Literature DB >> 2066353

Increased proteinase expression during tumor progression of cell lines down-modulated for TIMP levels: a new transformation paradigm? [corrected].

R Khokha1, P Waterhouse, P Lala, M Zimmer, D T Denhardt, R Khokka.   

Abstract

We have reported that down-modulation of tissue inhibitor of metalloproteinases (TIMP) by means of antisense RNA converts non-tumorigenic Swiss 3T3 cells into malignant cells capable of forming metastasizing tumors in nude mice [Science 243:947 (1989)]. We now describe changes in the expression of specific genes associated with tumor progression of two lines down-modulated with TIMP, LA1 and LA7. Six independent variant cell lines, generated from different primary tumors produced by LA1 and LA7, lacked (like LA1 and LA7) many characteristics of typical transformed cells. However, their tumorigenicity in nude mice was enhanced; tumors appeared with a shorter lag (1-3 weeks versus 8-10 weeks for the parental clones, LA1 and LA7) and grew very rapidly. Increases, substantial in some cases, in the expression of a cysteine proteinase, cathepsin L, and metalloproteinases homologous to rat transin (stromelysin) and transin-2 were characteristic of these variant clones. The mRNA levels encoding the transformation-associated secreted phosphoprotein (osteopontin) and the calcium-binding protein calcyclin were also augmented. No evidence for gene amplification was found, and we did not detect any change in the mRNA levels of the proto-oncogenes that were examined. These novel cell lines represent a new paradigm for the transformed cell. Our data suggest that a reduction in TIMP secretion enhances the cell's oncogenic capacity by altering the extracellular environment in a way conducive to further changes in gene expression necessary for tumor progression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066353     DOI: 10.1007/BF01630716

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.

Authors:  P Mignatti; E Robbins; D B Rifkin
Journal:  Cell       Date:  1986-11-21       Impact factor: 41.582

Review 2.  On the use of anti-sense RNA: down-regulation of mRNA encoding a metalloproteinase inhibitor.

Authors:  R Khokha; D T Denhardt
Journal:  Anticancer Res       Date:  1987 Jul-Aug       Impact factor: 2.480

Review 3.  Mechanisms of tumor progression.

Authors:  P C Nowell
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

4.  A method for isolation of intact, translationally active ribonucleic acid.

Authors:  G Cathala; J F Savouret; B Mendez; B L West; M Karin; J A Martial; J D Baxter
Journal:  DNA       Date:  1983

5.  Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts.

Authors:  J M Dong; E M Prence; G G Sahagian
Journal:  J Biol Chem       Date:  1989-05-05       Impact factor: 5.157

6.  Human and rat malignant-tumor-associated mRNAs encode stromelysin-like metalloproteinases.

Authors:  R Nicholson; G Murphy; R Breathnach
Journal:  Biochemistry       Date:  1989-06-13       Impact factor: 3.162

7.  Expression of extracellular matrix components is regulated by substratum.

Authors:  C H Streuli; M J Bissell
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

8.  The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L.

Authors:  R W Mason; S Gal; M M Gottesman
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

9.  Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts.

Authors:  A M Craig; G T Bowden; A F Chambers; M A Spearman; A H Greenberg; J A Wright; M McLeod; D T Denhardt
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

Review 10.  Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos
Journal:  Anticancer Res       Date:  1989 Sep-Oct       Impact factor: 2.480

View more
  4 in total

1.  The architecture of cancer.

Authors:  J Waxman; H Wasan
Journal:  BMJ       Date:  1992-11-28

Review 2.  Matrix metalloproteases and lung disease.

Authors:  C M O'Connor; M X FitzGerald
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

3.  Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.

Authors:  J Rehbock; P Buchinger; A Hermann; C Figueroa
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

4.  Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease.

Authors:  S R Bramhall; G W Stamp; J Dunn; N R Lemoine; J P Neoptolemos
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.